Prot #RSV-M-301: A Phase 3, Randomized, Observer-Blind, Placebo-Controlled, Group-Sequential Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine with Aluminum in Healthy Third-trimester Pregnant W

Project: Research project

Project Details

StatusFinished
Effective start/end date10/4/16 → 10/4/19

Funding

  • INC Research, LLC (Prot #RSV-M-301 // Prot #RSV-M-301)
  • Novavax, Inc. (Prot #RSV-M-301 // Prot #RSV-M-301)